Cataract Surgery

It is important that patients know cataract surgery is a routine, safe procedure that will improve their quality of life.

Orbis International physician spotlights the latest trends for cataract surgery training.

Surgeons must use caution to avoid pitfalls of complicated procedure

Surgeons seek best IOL match for patients after cataract surgery.

Results of the Alcon Eye on Cataract Survey highlight misconceptions about cataract surgery, revealing the need to educate the 50+ population on the procedure and treatment options.

The organization aims to educate patients and doctors on one of the leading causes of blindness worldwide.

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Erisa Yotsukura, MD, PhD, offered details of a study examining an IOL that transmits violet light and a second option that does not, and they believe this can affect differences in the choroidal thickness after cataract surgery.

With instructor-led sessions and haptic feedback, this first-of-its-kind eye surgery training creates an immersive experience with the look and feel of surgery in a human eye, without risks to patient safety.

Medicare reimbursements for complex cataract surgery are far lower than a simpler form of the surgery.

Procedure integrates femto, phaco in one instrument to address issues.

The company’s MINIject is the only commercially available MIGS implant targeting the supraciliary space.

Physician discusses preoperative assessments before procedure focusing on cornea.

According to the company, in a clinical trial of chloroprocaine hydrochloride ophthalmic gel in patients undergoing routine cataract surgery, patients treated with the gel did not require any supplemental treatment to complete the intended surgical procedure.

The study compared 126 IOL injectors of 13 IOL injector systems regarding the manufacturers’ recommended preoperative incision sizes to evaluate the intraoperative incision enlargement and postoperative incision sizes.

Surgeon notes there is no good solution for ending use of topical medications

Denise Visco, MD, MBA, discusses takeaway points from patient case #1 for post-operative inflammation management for routine cataract surgery.

Denise Visco, MD, MBA, reviews Inflammation management in a 68-year-old patient following routine cataract surgery.

According to the company, the IC-8 Apthera IOL is a wavefront-filtering intraocular lens for unilateral implantation in the non-dominant eye in patients who have as much as 1.5 D of corneal astigmatism in the implanted eye.

Investigators find a link with a postoperative prolonged steroid response.

According to UC Davis researchers, more needs to be done for the field to reflect ethnic and racial diversity across the country.

According to investigators, surgeons should be aware of the high prevalence of zonular weakness and cystoid macular edema, which may warrant additional preparation in these patients.

Ophthalmologists can reduce IOP and medications with endocyclophotocoagulation while in the eye.

Mark Packer, MD, speaks on his 2022 AAO poster: "Safety and Effectiveness of a New FDA-Approved Dispersive Ophthalmic Viscosurgical Device."

Matthew Emanuel, MD, of Glaucoma Associates of Texas, discusses some of the current trends in cataract surgery. He notes it is something that everyone deals with as they get older. It also can be an issue for pediatric patients. Emanuel also notes that it is important for physicians to be able to educate their patients on the disease.

While the surgeons reported that the BW filter provided higher contrast during nucleus and viscous removal and posterior capsular polishing, they subjectively reported no significant advantage of using a BW filter.

The procedure ensures the removal of cortical remnants, capsular fibrosis during cataract surgery.

ASCRS, AAO behind year-long drive for policy change, with Aetna dropping its requirement on July 1 for pre-authorization for cataract surgery, covering patients in 48 of 50 states.

OCS-01 is being reviewed for the treatment of inflammation and pain after cataract surgery, with the potential to become the first once-daily, topical and preservative-free corticosteroid for treating inflammation and pain following ocular surgery.